| 2025-06-25 |
详情>>
股本变动：
变动后总股本983.89万股
|
| 2025-05-16 |
股东大会：
将于2025-06-25召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Irit Arbel, Dr. Menghisteab Bairu, Prof. Jacob Frenkel, Mr. Nir Naor, Dr. Anthony Polverino, Mr. Uri Yablonka and Dr. Stacy Lindborg as members of our board of directors, or our Board, to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal;
2.To ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock, or our Common Stock, issuable upon the exercise of certain common warrant issued by us on April 1, 2025, or the Common Warrant, in an amount equal to or in excess of twenty percent (20%) of the shares of our Common Stock outstanding immediately prior to the issuance of such warrant, or the Issuance Proposal;
4.To approve amendments to the Company’s 2014 Stock Incentive Plan and the Company’s 2014 Global Share Option Plan (the “2014 Plans”) to increase the shared pool of shares available for issuance under the Company’s 2014 Plans by 2,000,000 shares from 906,666 shares to 2,906,666 shares;
5.To transact such other business that may properly come before the Annual Meeting and any adjournments or postponements of the Annual Meeting.
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-0.45美元,归母净利润-286.4万美元,同比去年增长15.79%
|
| 2025-05-15 |
财报披露：
美东时间 2025-05-15 盘前发布财报
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-2.31美元,归母净利润-1162.3万美元,同比去年增长32.39%
|
| 2025-01-01 |
详情>>
内部人交易：
FRENKEL JACOB A等共交易12笔
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.8美元,归母净利润-865万美元,同比去年增长25.52%
|
| 2024-10-01 |
复牌提示：
2024-09-30 19:50:00 停牌，复牌日期 2024-10-01 09:00:00
|
| 2024-09-26 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2024-08-16 |
股东大会：
将于2024-09-16召开股东大会
会议内容 ▼▲
- 1.To elect each of Dr. Irit Arbel, Dr. Menghisteab Bairu, Dr. Jacob Frenkel, Nir Naor, Dr. Anthony Polverino, Uri Yablonka and Dr. Stacy Lindborg as members of the Board of Directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal;
2.To ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2024;
3.To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 100,000,000 shares to 250,000,000 shares;
4.To approve amendments to the Company’s 2014 Stock Incentive Plan and the Company’s 2014 Global Share Option (the “2014 Plans”) to increase the shared pool of shares available for issuance under the Company’s 2014 Plans by 8,000,000 shares from 5,600,000 shares to 13,600,000 shares and extend the terms of the 2014 Plans by ten years each;
5.To authorize the Board of Directors of the Company, in its discretion, should it deem it to be appropriate and in the best interests of the Company and its stockholders, to amend the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding shares of Common Stock by a ratio between 1-for-5 and 1-for-15, inclusive, without further approval or authorization of the Company’s stockholders;
6.To approve, on a non-binding advisory basis, the frequency of holding future advisory votes regarding the compensation of the Company’s named executive officers every three years;
7.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers;
8.To transact such other business that may properly come before the Meeting and any adjournments or postponements of the Meeting.
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-0.09美元,归母净利润-594.2万美元,同比去年增长42.80%
|
| 2024-05-14 |
详情>>
业绩披露：
2024年一季报每股收益-0.05美元,归母净利润-340.1万美元,同比去年增长32.77%
|
| 2024-04-01 |
详情>>
业绩披露：
2023年年报每股收益-0.4美元,归母净利润-1719.2万美元,同比去年增长29.18%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.29美元,归母净利润-1161.4万美元,同比去年增长39.70%
|
| 2023-11-08 |
股东大会：
将于2023-12-18召开股东大会
会议内容 ▼▲
- 1.To elect each of Dr. Irit Arbel, Dr. Menghisteab Bairu, Dr. Jacob Frenkel, Nir Naor, Dr. Anthony Polverino and Uri Yablonka, as members of the Board of Directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal;
2.To ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2024;
3.To transact such other business that may properly come before the Meeting and any adjournments or postponements of the Meeting.
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-0.27美元,归母净利润-1038.8万美元,同比去年增长16.23%
|
| 2023-05-15 |
详情>>
业绩披露：
2023年一季报每股收益-0.14美元,归母净利润-505.9万美元,同比去年增长5.62%
|
| 2023-03-30 |
详情>>
业绩披露：
2022年年报每股收益-0.66美元,归母净利润-2427.7万美元,同比去年增长0.74%
|
| 2022-12-13 |
股东大会：
将于2023-01-10召开股东大会
会议内容 ▼▲
- 1.To elect each of Dr. Irit Arbel, Dr. June S. Almenoff, Dr. Jacob Frenkel, Dr. Anthony Polverino, Malcolm Taub, Uri Yablonka and Dr. Menghisteab Bairu as members of the Board of Directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal;
2.To ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the Company’s current fiscal year;
3.To transact such other business that may properly come before the Meeting and any adjournments or postponements of the Meeting.
|
| 2021-11-04 |
股东大会：
将于2021-12-14召开股东大会
会议内容 ▼▲
- 1.To elect each of Dr. Irit Arbel, Dr. June S. Almenoff, Dr. Jacob Frenkel, Dr. Anthony Polverino, Malcolm Taub, Uri Yablonka and Dr. Menghisteab Bairu as members of the Board of Directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the Company’s current fiscal year;
4.To transact such other business that may properly come before the Meeting and any adjournments or postponements of the Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-10-01 |
股东大会：
将于2020-11-10召开股东大会
会议内容 ▼▲
- 1.To elect each of Dr. Irit Arbel, Sankesh Abbhi, Dr. June S. Almenoff, Dr. Jacob Frenkel, Dr. Anthony Polverino, Malcolm Taub and Uri Yablonka as members of the Board of Directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal;
2.To approve amendments to the Company’s 2014 Stock Incentive Plan and the Company’s 2014 Global Share Option Plan to increase the shared pool of shares available for issuance under the Company’s current equity plans by 1,600,000 additional shares (from 4,000,000 to 5,600,000 shares) of the Company’s Common Stock;
3.To ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the Company’s current fiscal year;
4.To transact such other business that may properly come before the Meeting and any adjournments or postponements of the Meeting.
|
| 2019-10-25 |
股东大会：
将于2019-12-11召开股东大会
会议内容 ▼▲
- 1.To elect each of Dr. Irit Arbel, Dr. June S. Almenoff, Dr. Anthony Polverino, Chen Schor, Malcolm Taub and Uri Yablonka as members of the Board of Directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal;
2.To ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the Company’s current fiscal year;
3.To transact such other business that may properly come before the Meeting and any adjournments or postponements of the Meeting.
|
| 2018-10-10 |
股东大会：
将于2018-11-29召开股东大会
会议内容 ▼▲
- 1.To elect each of Dr. Irit Arbel, Dr. June S. Almenoff, Dr. Anthony Polverino, Chen Schor, Malcolm Taub and Uri Yablonka as members of the Board of Directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To approve, on a non-binding advisory basis, the frequency of holding future stockholder votes regarding the compensation of our named executive officers;
4.To approve amendments to the Company’s 2014 Stock Incentive Plan and the Company’s 2014 Global Share Option Plan to increase the shared pool of shares available for issuance under the Company’s current equity plans by 1,800,000 additional shares (from 2,200,000 to 4,000,000 shares) of Company Common Stock;
5.To ratify the appointment of Brightman Almagor Zohar & Co., a member of Deloitte Touche Tohmatsu Limited, as the Company’s independent registered public accounting firm for the Company’s current fiscal year;
6.To transact such other business that may properly come before the Meeting and any adjournments or postponements of the Meeting.
|
| 2017-09-14 |
股东大会：
将于2017-11-09召开股东大会
会议内容 ▼▲
- 1.To elect each of Dr. Irit Arbel, Dr. June S. Almenoff, Arturo O. Araya, Chen Schor, Dr. Robert Shorr, Malcolm Taub and Uri Yablonka as members of the board of directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified;
2.To ratify the appointment of Brightman Almagor Zohar & Co., a member of Deloitte Touche Tohmatsu Limited, as the Company’s independent registered public accounting firm for the current fiscal year;
3.To transact such other business that may properly come before the Meeting and any adjournments or postponements of the Meeting.
|
| 2016-05-11 |
股东大会：
将于2016-06-21召开股东大会
会议内容 ▼▲
- 1.To elect each of Dr. Irit Arbel, Mordechai Friedman, Alon Pinkas, Chen Schor, Dr. Robert Shorr, Malcolm Taub and Uri Yablonka as members of the board of directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified;
2.To approve an amendment to the Company’s 2014 Stock Incentive Plan to increase the shared pool of shares available for issuance under the Company’s equity plans by 1,600,000 additional shares (from 600,000 to 2,200,000 shares) of Company Common Stock;
3.To approve an amendment to the Company’s 2014 Global Share Option Plan to increase the shared pool of shares available for issuance under the Company’s equity plans by 1,600,000 additional shares (from 600,000 to 2,200,000 shares) of Company Common Stock;
4.To ratify the appointment of Brightman Almagor Zohar & Co., a member of Deloitte Touche Tohmatsu Limited, as the Company’s independent registered public accounting firm for the current fiscal year;
5.To transact such other business that may properly come before the Meeting and any adjournments or postponements of the Meeting.
|
| 2015-07-17 |
股东大会：
将于2015-08-26召开股东大会
会议内容 ▼▲
- 1. To elect each of Dr. Irit Arbel, Mordechai Friedman, Alon Pinkas, Chen Schor, Dr. Robert Shorr, Malcolm Taub and Uri Yablonka as members of the board of directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified;
2. To approve an amendment to the Company’s Certificate of Incorporation to reduce the number of authorized shares of our common stock from 800,000,000 to 100,000,000;
3. To approve, on an advisory basis, the compensation of our named executive officers;
4. To ratify the appointment of Brightman Almagor Zohar & Co., a member of Deloitte Touche Tohmatsu, as the Company’s independent registered public accounting firm for the current fiscal year;
5. To transact such other business that may properly come before the Meeting and any adjournments or postponements of the Meeting.
|